181 related articles for article (PubMed ID: 35524342)
1. Immune checkpoints in T cells during oncogenic γ-herpesvirus infections.
Münz C
J Med Virol; 2023 Jan; 95(1):e27840. PubMed ID: 35524342
[TBL] [Abstract][Full Text] [Related]
2. Molecular Mechanisms of Flavonoids against Tumor Gamma-Herpesviruses and Their Correlated Cancers-A Focus on EBV and KSHV Life Cycles and Carcinogenesis.
Hassan STS; Šudomová M
Int J Mol Sci; 2022 Dec; 24(1):. PubMed ID: 36613688
[TBL] [Abstract][Full Text] [Related]
3. Cancers associated with human gammaherpesviruses.
Wen KW; Wang L; Menke JR; Damania B
FEBS J; 2022 Dec; 289(24):7631-7669. PubMed ID: 34536980
[TBL] [Abstract][Full Text] [Related]
4. Co-Infection of the Epstein-Barr Virus and the Kaposi Sarcoma-Associated Herpesvirus.
Böni M; Rieble L; Münz C
Viruses; 2022 Dec; 14(12):. PubMed ID: 36560713
[TBL] [Abstract][Full Text] [Related]
5. Immunodeficiencies that predispose to pathologies by human oncogenic γ-herpesviruses.
Damania B; Münz C
FEMS Microbiol Rev; 2019 Mar; 43(2):181-192. PubMed ID: 30649299
[TBL] [Abstract][Full Text] [Related]
6. Co-infection and co-localization of Kaposi sarcoma-associated herpesvirus and Epstein-Barr virus in HIV-associated Kaposi sarcoma: a case report.
Julius P; Kang G; Siyumbwa S; Musumali J; Tso FY; Ngalamika O; Kaile T; Maate F; Moonga P; West JT; Angeletti P; Wood C
Front Cell Infect Microbiol; 2023; 13():1270935. PubMed ID: 37928187
[TBL] [Abstract][Full Text] [Related]
7. Natural killer cell responses to human oncogenic γ-herpesvirus infections.
Münz C
Semin Immunol; 2022 Mar; 60():101652. PubMed ID: 36162228
[TBL] [Abstract][Full Text] [Related]
8. Persistent KSHV Infection Increases EBV-Associated Tumor Formation In Vivo via Enhanced EBV Lytic Gene Expression.
McHugh D; Caduff N; Barros MHM; Rämer PC; Raykova A; Murer A; Landtwing V; Quast I; Styles CT; Spohn M; Fowotade A; Delecluse HJ; Papoudou-Bai A; Lee YM; Kim JM; Middeldorp J; Schulz TF; Cesarman E; Zbinden A; Capaul R; White RE; Allday MJ; Niedobitek G; Blackbourn DJ; Grundhoff A; Münz C
Cell Host Microbe; 2017 Jul; 22(1):61-73.e7. PubMed ID: 28704654
[TBL] [Abstract][Full Text] [Related]
9. CDK4/6 inhibitors sensitize gammaherpesvirus-infected tumor cells to T-cell killing by enhancing expression of immune surface molecules.
Wu Y; Shrestha P; Heape NM; Yarchoan R
J Transl Med; 2022 May; 20(1):217. PubMed ID: 35562811
[TBL] [Abstract][Full Text] [Related]
10. Epidemiology of Epstein-Barr virus, cytomegalovirus, and Kaposi's sarcoma-associated herpesvirus infections in peripheral blood leukocytes revealed by a multiplex PCR assay.
Nishiwaki M; Fujimuro M; Teishikata Y; Inoue H; Sasajima H; Nakaso K; Nakashima K; Sadanari H; Yamamoto T; Fujiwara Y; Ogawa N; Yokosawa H
J Med Virol; 2006 Dec; 78(12):1635-42. PubMed ID: 17063511
[TBL] [Abstract][Full Text] [Related]
11. Tumor Microenvironment Conditioning by Abortive Lytic Replication of Oncogenic γ-Herpesviruses.
Münz C
Adv Exp Med Biol; 2020; 1225():127-135. PubMed ID: 32030652
[TBL] [Abstract][Full Text] [Related]
12. Infection and immune control of human oncogenic γ-herpesviruses in humanized mice.
McHugh D; Caduff N; Murer A; Engelmann C; Deng Y; Zdimerova H; Zens K; Chijioke O; Münz C
Philos Trans R Soc Lond B Biol Sci; 2019 May; 374(1773):20180296. PubMed ID: 30955487
[TBL] [Abstract][Full Text] [Related]
13. Nanotechnology Frontiers in γ-Herpesviruses Treatments.
Granato M
Int J Mol Sci; 2021 Oct; 22(21):. PubMed ID: 34768838
[TBL] [Abstract][Full Text] [Related]
14. Probing Reconstituted Human Immune Systems in Mice With Oncogenic γ-Herpesvirus Infections.
Münz C
Front Immunol; 2020; 11():581419. PubMed ID: 33013936
[TBL] [Abstract][Full Text] [Related]
15. Modulation of Epstein-Barr-Virus (EBV)-Associated Cancers by Co-Infections.
Münz C
Cancers (Basel); 2023 Dec; 15(24):. PubMed ID: 38136285
[TBL] [Abstract][Full Text] [Related]
16. Gamma-herpesvirus neoplasia: a growing role for COX-2.
Shelby BD; Nelson A; Morris C
Microsc Res Tech; 2005 Nov; 68(3-4):120-9. PubMed ID: 16276519
[TBL] [Abstract][Full Text] [Related]
17. A prospective study of Kaposi's sarcoma-associated herpesvirus and Epstein-Barr virus in adults with human immunodeficiency virus-1.
Newton R; Carpenter L; Casabonne D; Beral V; Babiker A; Darbyshire J; Weller I; Weiss R; Kwan A; Bourboulia D; Munoz F; Lagos D; Boshoff C
Br J Cancer; 2006 May; 94(10):1504-9. PubMed ID: 16705315
[TBL] [Abstract][Full Text] [Related]
18. [EBV/KSHV co-infection: an effective partnership].
Gruffat H; Manet E
Med Sci (Paris); 2018 Jan; 34(1):79-82. PubMed ID: 29384100
[TBL] [Abstract][Full Text] [Related]
19. [Epstein-Barr virus (EBV) and Kaposi's sarcoma-associated herpesvirus (KSHV, HHV-8)].
Katano H
Uirusu; 2010 Dec; 60(2):237-45. PubMed ID: 21488336
[TBL] [Abstract][Full Text] [Related]
20. Mutual inhibition between Kaposi's sarcoma-associated herpesvirus and Epstein-Barr virus lytic replication initiators in dually-infected primary effusion lymphoma.
Jiang Y; Xu D; Zhao Y; Zhang L
PLoS One; 2008 Feb; 3(2):e1569. PubMed ID: 18253508
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
